LPOXY Therapeutics Acquires Assets to Advance C difficile Protection for Antibiotic Patients
CEO Larry D Sutton, MD, PhD, elaborates on the company’s strategy and the science behind SIDIPREV to prevent C difficile infections in hospitalized patients.